Terry Roemer
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$13.7MFederal grants as PI18 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
18 awards · $13.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 3, 2026 | NIH | SBIR Phase II Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics | $977K | Prokaryotics, Inc. |
| Sep 19, 2025 | NIH | SBIR Phase II Development of an active site inhibitor of Fks1 as a broad spectrum antifungal agent | $300K | Prokaryotics, Inc. |
| Apr 24, 2025 | NIH | SBIR Phase II Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics | $996K | Prokaryotics, Inc. |
| Jul 30, 2024 | NIH | STTR Phase II Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis | $296K | Prokaryotics, Inc. |
| Jun 5, 2024 | NIH | SBIR Phase II Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci | $975K | Prokaryotics, Inc. |
| Aug 15, 2023 | NIH | STTR Phase II Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis | $299K | Prokaryotics, Inc. |
| Jun 21, 2023 | NIH | SBIR Phase II Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci | $991K | Prokaryotics, Inc. |
| Aug 26, 2022 | NIH | SBIR Phase II Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics | $300K | Prokaryotics, Inc. |
| Jul 20, 2022 | NIH | SBIR Phase II Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | $1.0M | Prokaryotics, Inc. |
| Jul 8, 2022 | NIH | SBIR Phase II Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci | $999K | Prokaryotics, Inc. |
| Aug 16, 2021 | NIH | SBIR Phase II Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | $1.0M | Prokaryotics, Inc. |
| Jul 8, 2020 | NIH | SBIR Phase II Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae | $842K | Prokaryotics, Inc. |
| Nov 26, 2019 | NIH | SBIR Phase II Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci | $1.0M | Prokaryotics, Inc. |
| Jul 26, 2019 | NIH | SBIR Phase II Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | $296K | Prokaryotics, Inc. |
| Jul 1, 2019 | NIH | SBIR Phase II Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae | $1.8M | Prokaryotics, Inc. |
| Dec 24, 2018 | NIH | SBIR Phase II Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci | $1.0M | Prokaryotics, Inc. |
| Jun 14, 2018 | NIH | SBIR Phase II Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae | $300K | Prokaryotics, Inc. |
| Feb 2, 2018 | NIH | SBIR Phase II Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci | $300K | Prokaryotics, Inc. |
Peer ranks
Federal funding#27
Awards as PI#24
Patents#273
Companies
- Prokaryotics, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.